AusBiotech is calling for innovative approaches, contributions or analyses to include in their 2020 Australasian Biotechnology journals. AusBiotech is welcoming abstracts from valued members on medtech, digital health, and therapeutic trends and discoveries to illustrate the industry’s achievements and challenges being faced.
Australasian Biotechnology is AusBiotech’s official biannual journal, and published in April and October.
Editorials for the April edition should cover digital diagnostics, telemedicine, artificial intellingence, and empowering and engaging patients.
The October edition will focus on regenerative medicines, gene therapies, synthetic biology, and multi-drug resistant bacteria.
Abstracts for the April edition can be sent to Karen Parr, Communications Manager, by 7 February 2020.
If your abstract is accepted, the full article will be required on or before 18 February 2020. Article lengths are approximately 500 words (1 page) or 1,000 words (2 pages). High resolution photos to accompany articles are encouraged.
Articles are a member-benefit, however there is limited space and so articles are not guaranteed to be included. Abstracts are welcomed on research, business news, and sector trends for consideration at any time of the year.
With its informed and authoritative editorials, Australasian Biotechnology is a highly-effective communications vehicle for those wanting to reach out to stakeholders in the life sciences sector.The journal is mailed on a name-and-title basis to over 3,000 AusBiotech members and investors. Its contributions are written by the sector, for the sector. Readership includes companies, government and university departments, research institutes, biotechnology and professional services providers nationally, and in key overseas markets.